Immune regulation of multiple sclerosis by CD8+ T cells

Immunologic Research

Volumn 59, Issue 1-3, 2014, Pages 254-265

  Sinha, Sushmita ^a   Itani, Farah R ^a   Karandikar, Nitin J ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

Experimental autoimmune encephalomyelitis (EAE); Glatiramer acetate (GA); Immunoregulatory; Multiple sclerosis (MS)

Indexed keywords

GLATIRAMER;

AUTOIMMUNE DISEASE; CD8+ T LYMPHOCYTE; CYTOTOXICITY; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; HUMAN; IMMUNE RESPONSE; IMMUNOPATHOLOGY; IMMUNOREGULATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; T LYMPHOCYTE; ANIMAL; ART; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; IMMUNOLOGY; PATHOLOGY;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; HUMANS; IMMUNITY, CELLULAR; MULTIPLE SCLEROSIS; PORTRAITS AS TOPIC;

EID: 84905735685     PISSN: 0257277X     EISSN: 15590755     Source Type: Journal    
DOI: 10.1007/s12026-014-8529-9     Document Type: Review

References (85)

1. Anderson DW, Ellenberg JH, Leventhal CM, Reingold SC, Rodriguez M, Silberberg DH. Revised estimate of the prevalence of multiple sclerosis in the United States. Ann Neurol. 1992;31(3):333-6. doi:10.1002/ana.410310317.
2. Arnason BG. Relevance of experimental allergic encephalomyelitis to multiple sclerosis. Neurol Clin. 1983;1(3):765-82.
3. Martin R, McFarland HF, McFarlin DE. Immunological aspects of demyelinating diseases. Annu Rev Immunol. 1992;10:153-87. doi:10.1146/annurev. iy.10.040192.001101.
4. McFarlin DE, McFarland HF. Multiple sclerosis (first of two parts). N Engl J Med. 1982;307(19):1183-8. doi:10.1056/NEJM198211043071905. (Pubitemid 12037979)
5. Babbe H, Roers A, Waisman A, Lassmann H, Goebels N, Hohlfeld R, et al. Clonal expansions of CD8(+) T cells dominate the T cell infiltrate in active multiple sclerosis lesions as shown by micromanipulation and single cell polymerase chain reaction. J Exp Med. 2000;192(3):393-404. (Pubitemid 30629164)
6. Crawford MP, Yan SX, Ortega SB, Mehta RS, Hewitt RE, Price DA, et al. High prevalence of autoreactive, neuroantigen-specific CD8+ T cells in multiple sclerosis revealed by novel flow cytometric assay. Blood. 2004;103(11):4222-31. doi:10.1182/blood-2003-11-4025. (Pubitemid 38685367)
7. Antel J, Bania M, Noronha A, Neely S. Defective suppressor cell function mediated by T8+ cell lines from patients with progressive multiple sclerosis. J Immunol. 1986;137(11):3436-9. (Pubitemid 17193296)
8. Balashov KE, Khoury SJ, Hafler DA, Weiner HL. Inhibition ofT cell responses by activated human CD8+ T cells is mediated by interferon-gamma and is defective in chronic progressive multiple sclerosis. J Clin Investig. 1995;95(6):2711-9. doi:10.1172/JCI117973.
9. Baughman EJ, Mendoza JP, Ortega SB, Ayers CL, Greenberg BM, Frohman EM, et al. Neuroantigen-specific CD8+ regulatory T-cell function is deficient during acute exacerbation of multiple sclerosis. J Autoimmun. 2011;36(2):115-24. doi:10.1016/j.jaut.2010.12.003.
10. Karandikar NJ, Crawford MP, Yan X, Ratts RB, Brenchley JM, Ambrozak DR, et al. Glatiramer acetate (Copaxone) therapy induces CD8(+) T cell responses in patients with multiple sclerosis. J Clin Investig. 2002;109(5):641-9. doi:10.1172/JCI14380. (Pubitemid 34204843)
11. Tennakoon DK, Mehta RS, Ortega SB, Bhoj V, Racke MK, Karandikar NJ. Therapeutic induction of regulatory, cytotoxic CD8+ T cells in multiple sclerosis. J Immunol. 2006;176(11):7119-29. (Pubitemid 43787894)
12. Tyler AF, Mendoza JP, Firan M, Karandikar NJ. CD8 T cells are required for glatiramer acetate therapy in autoimmune demyelinating disease. PLoS One. 2013;8(6):e66772. doi:10.1371/journal.pone.0066772.
13. York NR, Mendoza JP, Ortega SB, Benagh A, Tyler AF, Firan M, et al. Immune regulatory CNS-reactive CD8+ T cells in experimental autoimmune encephalomyelitis. J Autoimmun. 2010;35(1):33-44. doi:10.1016/j.jaut.2010.01. 003.
14. Tsai S, Shameli A, Yamanouchi J, Clemente-Casares X, Wang J, Serra P, et al. Reversal of autoimmunity by boosting memory-like autoregulatory T cells. Immunity. 2010;32(4):568-80. doi:10.1016/j.immuni.2010.03.015.
15. Brimnes J, Allez M, Dotan I, Shao L, Nakazawa A, Mayer L. Defects in CD8+ regulatory T cells in the lamina propria of patients with inflammatory bowel disease. J Immunol. 2005;174(9):5814-22. (Pubitemid 40593226)
16. Cho BA, Sim JH, Park JA, Kim HW, Yoo WH, Lee SH, et al. Characterization of effector memory CD8+ T cells in the synovial fluid of rheumatoid arthritis. J Clin Immunol. 2012;32(4):709-20. doi:10.1007/s10875-012-9674-3.
17. Ayers CL, Mendoza JP, Sinha S, Cunnusamy K, Greenberg BM, Frohman EM, et al. Modulation of immune function occurs within hours of therapy initiation for multiple sclerosis. Clin Immunol. 2013;147(2):105-19. doi:10.1016/j.clim.2013. 02.015.
18. Ortega SB, Kashi VP, Tyler AF, Cunnusamy K, Mendoza JP, Karandikar NJ. The disease-ameliorating function of autoregulatory CD8 T cells is mediated by targeting of encephalitogenic CD4 T cells in experimental autoimmune encephalomyelitis. J Immunol. 2013;191(1):117-26. doi:10.4049/jimmunol.1300452.
19. Cunnusamy KBE, Franco J, Ortega SB, Sinha S, Chaudhary P, Greenberg BM, Frohman EM, Karandikar NJ. Disease exacerbation of multiple sclerosis is characterized by loss of terminally differentiated autoregulatory CD8+ T cells. Clin Immunol. 2014;152(1-2):115-26. doi:10.1016/j.clim.2014.03.005.
20. Biegler BW, Yan SX, Ortega SB, Tennakoon DK, Racke MK, Karandikar NJ. Glatiramer acetate (GA) therapy induces a focused, oligoclonal CD8+ T-cell repertoire in multiple sclerosis. J Neuroimmunol. 2006;180(1-2):159-71. doi:10.1016/j.jneuroim.2006.07.015. (Pubitemid 44692328)
21. Biegler BW, Yan SX, Ortega SB, Tennakoon DK, Racke MK, Karandikar NJ. Clonal composition of neuroantigen-specific CD8+ and CD4+ T-cells in multiple sclerosis. J Neuroimmunol. 2011;234(1-2):131-40. doi:10.1016/j.jneuroim.2011.02. 001.
22. Racke MK, Lovett-Racke AE, Karandikar NJ. The mechanism of action of glatiramer acetate treatment in multiple sclerosis. Neurology. 2010;74(Suppl 1):S25-30. doi:10.1212/WNL.0b013e3181c97e39.
23. Ratts RB, Karandikar NJ, Hussain RZ, Choy J, Northrop SC, Lovett-Racke AE, et al. Phenotypic characterization of autoreactive T cells in multiple sclerosis. J Neuroimmunol. 2006;178(1-2):100-10. doi:10.1016/j.jneuroim.2006.06. 010. (Pubitemid 44354819)
24. Ratts RB, Lovett-Racke AE, Choy J, Northrop SC, Hussain RZ, Karandikar NJ, et al. CD28-CD576 T cells predominate in CD8 responses to glatiramer acetate. J Neuroimmunol. 2006;178(1-2):117-29. doi:10.1016/j.jneuroim.2006.06. 001. (Pubitemid 44307345)
25. Jiang H, Canfield SM, Gallagher MP, Jiang HH, Jiang Y, Zheng Z, et al. HLA-E-restricted regulatory CD8(+) T cells are involved in development and control of human autoimmune type 1 diabetes. J Clin Investig. 2010;120(10):3641-50. doi:10.1172/JCI43522.
26. Carvalheiro H, da Silva JA, Souto-Carneiro MM. Potential roles for CD8(+) T cells in rheumatoid arthritis. Autoimmun Rev. 2013;12(3):401-9. doi:10.1016/j.autrev.2012.07.011.
27. Correale J, Villa A. Role of CD8+ CD25+ Foxp3+ regulatory T cells in multiple sclerosis. Ann Neurol. 2010;67(5):625-38. doi:10.1002/ana.21944.
28. Davila E, Kang YM, Park YW, Sawai H, He X, Pryshchep S, et al. Cell-based immunotherapy with suppressor CD8+ T cells in rheumatoid arthritis. J Immunol. 2005;174(11):7292-301. (Pubitemid 40705699)
29. Tada Y, Ho A, Koh DR, Mak TW. Collagen-induced arthritis in CD4- or CD8- deficient mice: cd8+ T cells play a role in initiation and regulate recovery phase of collagen-induced arthritis. J Immunol. 1996;156(11):4520-6. (Pubitemid 26165856)
30. Penninger JM, Neu N, Timms E, Wallace VA, Koh DR, Kishihara K, et al. The induction of experimental autoimmune myocarditis in mice lacking CD4 or CD8 molecules [corrected]. J Exp Med. 1993;178(5):1837-42. (Pubitemid 23318467)
31. Stuart PM, Summers B, Morris JE, Morrison LA, Leib DA. CD8(+) T cells control corneal disease following ocular infection with herpes simplex virus type 1. J Gen Virol. 2004;85(Pt 7):2055-63. doi:10.1099/vir.0.80049-0. (Pubitemid 39023285)
32. Jiang H, Zhang SI, Pernis B. Role of CD8+ T cells in murine experimental allergic encephalomyelitis. Science. 1992;256(5060):1213-5.
33. Lee YH, Ishida Y, Rifa'i M, Shi Z, Isobe K, Suzuki H. Essential role of CD8+ CD122+ regulatory T cells in the recovery from experimental autoimmune encephalomyelitis. J Immunol. 2008;180(2):825-32.
34. Rifa'i M, Kawamoto Y, Nakashima I, Suzuki H. Essential roles of CD8+ CD122+ regulatory T cells in the maintenance of T cell homeostasis. J Exp Med. 2004;200(9):1123-34. doi:10.1084/jem.20040395. (Pubitemid 39507052)
35. Crucian B, Dunne P, Friedman H, Ragsdale R, Pross S, Widen R. Alterations in levels of CD28-/CD8+ suppressor cell precursor and CD45RO+/CD4+ memory T lymphocytes in the peripheral blood of multiple sclerosis patients. Clin Diagn Lab Immunol. 1995;2(2):249-52.
36. Najafian N, Chitnis T, Salama AD, Zhu B, Benou C, Yuan X, et al. Regulatory functions of CD8+ CD28- T cells in an autoimmune disease model. J Clin Investig. 2003;112(7):1037-48. doi:10.1172/JCI17935. (Pubitemid 38056319)
37. Hu D, Ikizawa K, Lu L, Sanchirico ME, Shinohara ML, Cantor H. Analysis of regulatory CD8 T cells in Qa-1-deficient mice. Nat Immunol. 2004;5(5):516-23. doi:10.1038/ni1063. (Pubitemid 38660464)
38. Jiang H, Braunstein NS, Yu B, Winchester R, Chess L. CD8+ T cells control the TH phenotype of MBP-reactive CD4+ T cells in EAE mice. Proc Natl Acad Sci USA. 2001;98(11):6301-6. doi:10.1073/pnas.101123098. (Pubitemid 32488234)
39. Correale J, Villa A. Isolation and characterization of CD8+ regulatory T cells in multiple sclerosis. J Neuroimmunol. 2008;195(1-2):121-34. doi:10.1016/j.jneuroim.2007.12.004.
40. Pannemans K, Broux B, Goris A, Dubois B, Broekmans T, Van Wijmeersch B, et al. HLA-E restricted CD8+ T cell subsets are phenotypically altered in multiple sclerosis patients. Multiple sclerosis. 2013;. doi:10.1177/ 1352458513509703.
41. Shi Z, Okuno Y, Rifa'i M, Endharti AT, Akane K, Isobe K, et al. Human CD8+ CXCR3+ T cells have the same function as murine CD8+ CD122+ Treg. Eur J Immunol. 2009;39(8):2106-19. doi:10.1002/eji.200939314.
42. Lu L, Cantor H. Generation and regulation of CD8(+) regulatory T cells. Cell Mol Immunol. 2008;5(6):401-6. doi:10.1038/cmi.2008.50.
43. Jurgens B, Hainz U, Fuchs D, Felzmann T, Heitger A. Interferon-gamma- triggered indoleamine 2,3-dioxygenase competence in human monocyte-derived dendritic cells induces regulatory activity in allogeneic T cells. Blood. 2009;114(15):3235-43. doi:10.1182/blood-2008-12-195073.
44. Martini M, Testi MG, Pasetto M, Picchio MC, Innamorati G, Mazzocco M, et al. IFN-gamma-mediated upmodulation of MHC class I expression activates tumor-specific immune response in a mouse model of prostate cancer. Vaccine. 2010;28(20):3548-57. doi:10.1016/j.vaccine.2010.03.007.
45. Wang Z, Hong J, Sun W, Xu G, Li N, Chen X, et al. Role of IFN-gamma in induction of Foxp3 and conversion of CD4+ CD25- T cells to CD4+ Tregs. J Clin Investig. 2006;116(9):2434-41. doi:10.1172/JCI25826. (Pubitemid 44330142)
46. Beeston T, Smith TR, Maricic I, Tang X, Kumar V. Involvement of IFN-gamma and perforin, but not Fas/FasL interactions in regulatory T cell-mediated suppression of experimental autoimmune encephalomyelitis. J Neuroimmunol. 2010;229(1-2):91-7. doi:10.1016/j.jneuroim.2010.07.007.
47. Tang X, Maricic I, Purohit N, Bakamjian B, Reed-Loisel LM, Beeston T, et al. Regulation of immunity by a novel population of Qa-1-restricted CD8alphaalpha + TCRalphabeta + T cells. J Immunol. 2006;177(11):7645-55. (Pubitemid 44846279)
48. Kim HJ, Verbinnen B, Tang X, Lu L, Cantor H. Inhibition of follicular T-helper cells by CD8(+) regulatory T cells is essential for self tolerance. Nature. 2010;467(7313):328-32. doi:10.1038/nature09370.
49. Cone RE, Chattopadhyay S, Sharafieh R, Lemire Y, O'Rourke J, Flavell RA, et al. T cell sensitivity to TGF-beta is required for the effector function but not the generation of splenic CD8+ regulatory T cells induced via the injection of antigen into the anterior chamber. Int Immunol. 2009;21(5):567-74. doi:10.1093/intimm/dxp023.
50. Ozenci V, Kouwenhoven M, Huang YM, Kivisakk P, Link H. Multiple sclerosis is associated with an imbalance between tumour necrosis factor-alpha (TNF-alpha)- and IL-10-secreting blood cells that is corrected by interferon-beta (IFN-beta) treatment. Clin Exp Immunol. 2000;120(1):147-53. (Pubitemid 30176912)
51. Huang WX, Huang P, Link H, Hillert J. Cytokine analysis in multiple sclerosis by competitive RT - PCR: a decreased expression of IL-10 and an increased expression of TNF-alpha in chronic progression. Multiple sclerosis. 1999;5(5):342-8. (Pubitemid 29505049)
52. Calabresi PA, Martin R, Jacobson S. Chemokines in chronic progressive neurological diseases: HTLV-1 associated myelopathy and multiple sclerosis. J Neurovirol. 1999;5(1):102-8. (Pubitemid 29051884)
53. Frisullo G, Nociti V, Iorio R, Patanella AK, Caggiula M, Marti A, et al. Regulatory T cells fail to suppress CD4T+ -bet + T cells in relapsing multiple sclerosis patients. Immunology. 2009;127(3):418-28. doi:10.1111/j.1365-2567. 2008.02963.x.
54. Sellner J, Koczi W, Harrer A, Oppermann K, Obregon-Castrillo E, Pilz G, et al. Glatiramer acetate attenuates the pro-migratory profile of adhesion molecules on various immune cell subsets in multiple sclerosis. Clin Exp Immunol. 2013;173(3):381-9. doi:10.1111/cei.12125.
55. Keith AB, Arnon R, Teitelbaum D, Caspary EA, Wisniewski HM. The effect of Cop 1, a synthetic polypeptide, on chronic relapsing experimental allergic encephalomyelitis in guinea pigs. J Neurol Sci. 1979;42(2):267-74. (Pubitemid 9183660)
56. Teitelbaum D, Meshorer A, Hirshfeld T, Arnon R, Sela M. Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide. Eur J Immunol. 1971;1(4):242-8. doi:10.1002/eji.1830010406.
57. Teitelbaum D, Webb C, Bree M, Meshorer A, Arnon R, Sela M. Suppression of experimental allergic encephalomyelitis in Rhesus monkeys by a synthetic basic copolymer. Clin Immunol Immunopathol. 1974;3(2):256-62.
58. Teitelbaum D, Webb C, Meshorer A, Arnon R, Sela M. Suppression by several synthetic polypeptides of experimental allergic encephalomyelitis induced in guinea pigs and rabbits with bovine and human basic encephalitogen. Eur J Immunol. 1973;3(5):273-9. doi:10.1002/eji.1830030505.
59. Abramsky O, Teitelbaum D, Arnon R. Effect of a synthetic polypeptide (COP 1) on patients with multiple sclerosis and with acute disseminated encephalomeylitis. Preliminary report. J Neurol Sci. 1977;31(3):433-8. (Pubitemid 8055812)
60. Bornstein MB, Miller AI, Teitelbaum D, Arnon R, Sela M. Multiple sclerosis: trial of a synthetic polypeptide. Ann Neurol. 1982;11(3):317-9. doi:10.1002/ana.410110314. (Pubitemid 12183665)
61. Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The copolymer 1 multiple sclerosis study group. Neurology. 1995;45(7):1268-76.
62. Johnson KP, Brooks BR, Ford CC, Goodman A, Guarnaccia J, Lisak RP, et al. Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. copolymer 1 multiple sclerosis study group. Multiple Sclerosis. 2000;6(4):255-66.
63. Brenner T, Arnon R, Sela M, Abramsky O, Meiner Z, Riven-Kreitman R, et al. Humoral and cellular immune responses to copolymer 1 in multiple sclerosis patients treated with copaxone. J Neuroimmunol. 2001;115(1-2):152-60. (Pubitemid 32245663)
64. Duda PW, Krieger JI, Schmied MC, Balentine C, Hafler DA. Human and murine CD4 T cell reactivity to a complex antigen: recognition of the synthetic random polypeptide glatiramer acetate. J Immunol. 2000;165(12):7300-7. (Pubitemid 32001210)
65. Duda PW, Schmied MC, Cook SL, Krieger JI, Hafler DA. Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis. J Clin Investig. 2000;105(7):967-76. doi:10.1172/JCI8970. (Pubitemid 30203069)
66. Farina C, Then Bergh F, Albrecht H, Meinl E, Yassouridis A, Neuhaus O et al. Treatment of multiple sclerosis with copaxone (COP): elispot assay detects COP-induced interleukin-4 and interferon-gamma response in blood cells. Brain J Neurol. 2001;124(Pt 4):705-719. (Pubitemid 32303830)
67. Neuhaus O, Farina C, Yassouridis A, Wiendl H, Then Bergh F, Dose T et al. Multiple sclerosis: comparison of copolymer-1-reactive T cell lines from treated and untreated subjects reveals cytokine shift from T helper 1 to T helper 2 cells. Proceedings of the National Academy of Sciences of the United States of America. 2000; 97(13):7452-7457. (Pubitemid 30431484)
68. Qin Y, Zhang DQ, Prat A, Pouly S, Antel J. Characterization of T cell lines derived from glatiramer-acetate-treated multiple sclerosis patients. J Neuroimmunol. 2000;108(1-2):201-6. (Pubitemid 30438768)
69. Hong J, Li N, Zhang X, Zheng B, Zhang JZ. Induction of CD4+ CD25+ regulatory T cells by copolymer-I through activation of transcription factor Foxp3. Proc Natl Acad Sci USA. 2005;102(18):6449-54. doi:10.1073/pnas. 0502187102. (Pubitemid 40617463)
70. Weber MS, Prod'homme T, Youssef S, Dunn SE, Rundle CD, Lee L, et al. Type II monocytes modulate T cell-mediated central nervous system autoimmune disease. Nat Med. 2007;13(8):935-43. doi:10.1038/nm1620. (Pubitemid 47222047)
71. Begum-Haque S, Sharma A, Christy M, Lentini T, Ochoa-Reparaz J, Fayed IF, et al. Increased expression of B cell-associated regulatory cytokines by glatiramer acetate in mice with experimental autoimmune encephalomyelitis. J Neuroimmunol. 2010;219(1-2):47-53. doi:10.1016/j.jneuroim.2009.11.016.
72. Kala M, Rhodes SN, Piao WH, Shi FD, Campagnolo DI, Vollmer TL. B cells from glatiramer acetate-treated mice suppress experimental autoimmune encephalomyelitis. Exp Neurol. 2010;221(1):136-45. doi:10.1016/j.expneurol.2009. 10.015.
73. Jurewicz A, Biddison WE, Antel JP. MHC class I-restricted lysis of human oligodendrocytes by myelin basic protein peptide-specific CD8 T lymphocytes. J Immunol. 1998;160(6):3056-9. (Pubitemid 28136763)
74. Tzartos JS, Friese MA, Craner MJ, Palace J, Newcombe J, Esiri MM, et al. Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis. Am J Pathol. 2008;172(1):146-55. doi:10.2353/ajpath.2008.070690. (Pubitemid 351186376)
75. Annibali V, Ristori G, Angelini DF, Serafini B, Mechelli R, Cannoni S, et al. CD161 (high) CD8+ T cells bear pathogenetic potential in multiple sclerosis. Brain J Neurol. 2011;134(Pt 2):542-54. doi:10.1093/brain/awq354.
76. Jilek S, Schluep M, Rossetti AO, Guignard L, Le Goff G, Pantaleo G, et al. CSF enrichment of highly differentiated CD8+ T cells in early multiple sclerosis. Clin Immunol. 2007;123(1):105-13. doi:10.1016/j.clim.2006.11.004. (Pubitemid 46401506)
77. Bania MB, Antel JP, Reder AT, Nicholas MK, Arnason BG. Suppressor and cytolytic cell function in multiple sclerosis: effects of cyclosporine A and interleukin 2. J Clin Investig. 1986;78(2):582-6. doi:10.1172/JCI112612. (Pubitemid 16074098)
78. Huseby ES, Liggitt D, Brabb T, Schnabel B, Ohlen C, Goverman J. A pathogenic role for myelin-specific CD8(+) T cells in a model for multiple sclerosis. J Exp Med. 2001;194(5):669-76. (Pubitemid 32844776)
79. Ford ML, Evavold BD. Specificity, magnitude, and kinetics of MOG-specific CD8+ T cell responses during experimental autoimmune encephalomyelitis. Eur J Immunol. 2005;35(1):76-85. doi:10.1002/eji.200425660. (Pubitemid 40123854)
80. Sun D, Whitaker JN, Huang Z, Liu D, Coleclough C, Wekerle H, et al. Myelin antigen-specific CD8+ T cells are encephalitogenic and produce severe disease in C57BL/6 mice. J Immunol. 2001;166(12):7579-87. (Pubitemid 32525639)
81. Mars LT, Bauer J, Gross DA, Bucciarelli F, Firat H, Hudrisier D, et al. CD8 T cell responses to myelin oligodendrocyte glycoprotein-derived peptides in humanized HLA-A*0201-transgenic mice. J Immunol. 2007;179(8):5090-8.
82. Saxena A, Bauer J, Scheikl T, Zappulla J, Audebert M, Desbois S, et al. Cutting edge: multiple sclerosis-like lesions induced by effector CD8 T cells recognizing a sequestered antigen on oligodendrocytes. J Immunol. 2008;181(3):1617-21.
83. Saitoh O, Abiru N, Nakahara M, Nagayama Y. CD8+ CD122+ T cells, a newly identified regulatory T subset, negatively regulate Graves' hyperthyroidism in a murine model. Endocrinology. 2007;148(12):6040-6. doi:10.1210/en.2007-0300. (Pubitemid 350146196)
84. Endharti AT, Okuno Y, Shi Z, Misawa N, Toyokuni S, Ito M, et al. CD8+ CD122+ regulatory T cells (Tregs) and CD4+ Tregs cooperatively prevent and cure CD4+ cell-induced colitis. J Immunol. 2011;186(1):41-52. doi:10.4049/jimmunol. 1000800.
85. Wang R, Han G, Song L, Wang J, Chen G, Xu R, et al. CD8+ regulatory T cells are responsible for GAD-IgG gene-transferred tolerance induction in NOD mice. Immunology. 2009;126(1):123-31. doi:10.1111/j.1365-2567.2008.02884.x.